Van beleggers
voor beleggers
desktop iconMarkt Monitor

Inloggen

  • Geen account? Registreren

Wachtwoord vergeten?

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel arGEN-X BRU:ARGX.BL, NL0010832176

  • 336,300 24 jun 2022 17:36
  • -3,700 (-1,09%) Dagrange 335,200 - 353,000
  • 108.815 Gem. (3M) 84K

Argenx stoomt richting eerste medicijn op de markt

1.783 Posts
Pagina: «« 1 ... 23 24 25 26 27 ... 90 »» | Laatste | Omlaag ↓
  1. forum rang 6 Egomarinus 6 januari 2021 14:15
    quote:

    Tuut schreef op 6 januari 2021 13:41:

    Iemand even per ongeluk op verkoop knop gedrukt?
    Volgens mij velen die teleurgesteld zijn dat de FDA aanvraag niet ingediend is eind 2020 zoals ze gemeld hadden het te doen.

    Ik blijf steevast zitten en twijfel zelfs om nog wat bij te kopen voor VS opent.

    Gr Ego
  2. forum rang 4 Piddybull. 6 januari 2021 22:04
    argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China



    Collaboration to expand and accelerate global development of efgartigimod; expected to allow argenx to more rapidly advance new potential indications into clinical development each year
    Zai Lab granted exclusive rights to develop and commercialize efgartigimod in Greater China
    argenx to receive $75 million in upfront Zai Lab equity and $100 million in near-term milestone and other payments
    Regulated Information/Inside Information

    Breda, the Netherlands, Shanghai and San Francisco – Jan. 6, 2021 – argenx SE (Euronext & NASDAQ: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, and Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced an exclusive license agreement for the development and commercialization of efgartigimod in Greater China, including mainland China, Hong Kong, Taiwan and Macau.

    “Through this collaboration with Zai Lab, we are expanding our global footprint in one of the world’s fastest growing markets and reaching more people living with severe autoimmune diseases. By leveraging Zai Lab’s strong local expertise within Greater China and proven development capabilities, we aim to provide broad access to efgartigimod in these important markets as well as accelerate the number of autoimmune indications in clinical development,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx. “We believe that Zai Lab is the ideal partner for us ahead of our first potential approval of efgartigimod in generalized myasthenia gravis (gMG) in the U.S. and we are aligned in our mutual passion to bring potential innovative immunology therapies to patients in need.”

    “argenx is building a leading immunology company and we are excited to collaborate with them during this important time. Efgartigimod is being evaluated in a broad range of autoimmune diseases and we look forward to bringing this potentially first-in-class product to patients in Greater China,” said Dr. Samantha Du, Founder, Chairperson and Chief Executive Officer of Zai Lab. “This collaboration also significantly expands and strengthens our pipeline in severe autoimmune diseases, where there is an urgent and serious need for new therapeutic options.”

    “There are an estimated 200,000 people living with MG in China,” said Dr. Harald Reinhart, Chief Medical Officer for Autoimmune and Infectious Diseases, Zai Lab. “The unmet medical need is significant for these patients, with very limited treatment options. We believe efgartigimod has a promising profile that, if approved, can potentially change the treatment paradigm not only of gMG but of other autoimmune diseases.”
    Under the terms of the agreement, Zai Lab obtains the exclusive right to develop and commercialize efgartigimod in Greater China. Zai Lab will recruit Chinese patients to argenx’s global registrational trials for the development of efgartigimod. Additionally, this agreement is expected to allow argenx to accelerate efgartigimod development by initiating multiple Phase 2 proof-of-concept trials in new autoimmune indications.
    argenx will receive $175 million in collaboration payments, comprised of a $75 million upfront payment in the form of 568,182 newly issued Zai Lab shares calculated at a price of $132.00 per share, $75 million as a guaranteed non-creditable, non-refundable development cost-sharing payment, and an additional $25 million milestone payment upon approval of efgartigimod in the U.S. argenx is also eligible to receive tiered royalties (mid-teen to low-twenties on a percentage basis) based on annual net sales of efgartigimod in Greater China.

    About Efgartigimod

    Efgartigimod is an investigational antibody fragment designed to reduce disease-causing immunoglobulin G (IgG) antibodies and block the IgG recycling process. Efgartigimod binds to the neonatal Fc receptor (FcRn), which is widely expressed throughout the body and plays a central role in rescuing IgG antibodies from degradation. Blocking FcRn reduces IgG antibody levels, representing a logical potential therapeutic approach for several autoimmune diseases known to be driven by disease-causing IgG antibodies, including: myasthenia gravis (MG), a chronic disease that causes muscle weakness; pemphigus vulgaris (PV), a chronic disease characterized by severe blistering of the skin; immune thrombocytopenia (ITP), a chronic bruising and bleeding disease; and chronic inflammatory demyelinating polyneuropathy (CIDP), a neurological disease leading to impaired motor function.

    About argenx

    argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx has offices in Belgium, the United States, and Japan. For more information, visit www.argenx.com and follow us on LinkedIn at www.linkedin.com/company/argenx/.

    About Zai Lab

    Zai Lab (NASDAQ:ZLAB; HKEX: 9688) is an innovative commercial-stage biopharmaceutical company focused on bringing transformative medicines for cancer and infectious and autoimmune diseases to patients in China and around the world. We aim to address significant unmet medical needs in large, fast-growing segments of the pharmaceutical market. To that end, our experienced team has secured partnerships with leading global biopharmaceutical companies in order to generate a broad pipeline of innovative marketed products and drug candidates. We have also built an in-house team with strong drug discovery and translational research capabilities and are establishing a pipeline of proprietary drug candidates with global rights. Our vision is to become a leading global biopharmaceutical company, discovering, developing, manufacturing and commercializing our portfolio in order to impact human health worldwide.

    For additional information about the company, please visit www.zailaboratory.com or follow us on Linkedin at www.linkedin.com/company/zai-lab/myco... and Twitter at www.twitter.com/ZaiLab_Global.

    argenx Contacts

  3. forum rang 7 de tuinman 7 januari 2021 11:38
    quote:

    Egomarinus schreef op 6 januari 2021 14:15:

    [...]Volgens mij velen die teleurgesteld zijn dat de FDA aanvraag niet ingediend is eind 2020 zoals ze gemeld hadden het te doen.

    Ik blijf steevast zitten en twijfel zelfs om nog wat bij te kopen voor VS opent.

    Gr Ego
    Het lijkt mij een logische verklaring dat deze aanvraag vertraging heeft opgelopen, doordat deze instanties enorm hard gewerkt hebben aan de corona-vaccins.
  4. Tuut 7 januari 2021 13:55


    Zai Lab

    Argenx ARGX-1,04% maakte woensdagavond bekend dat het een strategische samenwerking aangaat met Zai Lab, een Chinees biofarmabedrijf uit Shanghai dat een notering heeft op Nasdaq. Het is de bedoeling de wereldwijde ontwikkeling van het topmiddel efgartigimod te versnellen en nieuwe potentiële indicaties te onderzoeken. Zai Lab krijgt tegelijk de exclusieve rechten op de ontwikkeling en commercialisering van efgartigimod in Groot-China (China, Hongkong, Taiwan en Macau).

    In ruil ontvangt Argenx van Zai Lab een aanvangsbetaling van 75 miljoen dollar in de vorm van nieuwe aandelen Zai Lab. Daar kunnen later 100 miljoen dollar aan mijlpaal- en andere betalingen bij komen. Argenx zal ook royalty's krijgen op de verkoop van efgartigimod in de regio Groot-China.

    Analisten reageren afwachtend. Kepler Cheuvreux verandert niets aan zijn advies (houden) en koersdoel (200 euro). ‘De commercialisering van efgartigimod buiten de VS, EU-5 en Japan is in het huidige stadium niet inbegrepen in ons waarderingsmodel, aangezien we dit als een ‘upside’ beschouwen’, klinkt het.

    Idem dito bij Degroof Petercam. Zai Lab is een sterke lokale speler die de ontwikkeling en commercialisering van efgartigimod in China ter hand kan nemen, klinkt het. Maar ‘aangezien de ontwikkeling in China nog niet van start is gegaan, kennen we geen waardering voor efga in dit land toe’. Thomas Guillot blijft dan ook bij ‘houden’ en zijn koersdoel van 190 euro.

    Na de sterke jaarprestatie in 2020 gaan de winstnemingen bij Argenx voort: het aandeel zakt 1,4 procent tot 227,40 euro.
    bron de tijd.

    Mij lijkt dit onzettend belangrijke stap in commercialisering maakte woensdagavond bekend dat het een strategische samenwerking aangaat met Zai Lab, een Chinees biofarmabedrijf uit Shanghai dat een notering heeft op Nasdaq. Het is de bedoeling de wereldwijde ontwikkeling van het topmiddel efgartigimod te versnellen en nieuwe potentiële indicaties te onderzoeken
1.783 Posts
Pagina: «« 1 ... 23 24 25 26 27 ... 90 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord

Direct naar Forum

arGEN-X Meer »

Koers 336,300   Verschil -3,70 (-1,09%)
Laag 335,200   Volume 108.815
Hoog 353,000   Gem. Volume 84.035
24 jun 2022 17:36
Premium

KOPEN OF VERKOPEN?

Het laatste advies leest u als IEX Premium-lid

Ontdek Premium

arGEN-X Nieuws

  1. 18 dec Argenx krijgt groen licht FDA

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links